Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

ClinicalTrials.gov ID: NCT06058013

Public ClinicalTrials.gov record NCT06058013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Study identification

NCT ID
NCT06058013
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Enrollment
430 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 19, 2023
Primary completion
May 5, 2026
Completion
Jun 16, 2026
Last update posted
Jul 5, 2026

2023 – 2026

United States locations

U.S. sites
57
U.S. states
19
U.S. cities
45
Facility City State ZIP Site status
Neumora Investigator Site Encino California 91316
Neumora Investigator Site Garden Grove California 92845
Neumora Investigator Site Los Alamitos California 90720
Neumora Investigator Site Newport Beach California 92660
Neumora Investigator Site Orange California 92868
Neumora Investigator Site Santa Ana California 92704
Neumora Investigator Site Norwalk Connecticut 06851
Neumora Investigator Site Bradenton Florida 34205
Neumora Investigator Site Hollywood Florida 33024
Neumora Investigator Site Homestead Florida 33032
Neumora Investigator Site Lauderhill Florida 33161
Neumora Investigator Site Maitland Florida 32751
Neumora Investigator Sites Miami Florida 33122
Neumora Investigator Site Miami Florida 33126
Neumora Investigator Site Miami Florida 33133
Neumora Investigator Site Miami Florida 33137
Neumora Investigator Site Miami Florida 33186
Neumora Investigator Site Miami Lakes Florida 33014
Neumora Investigator Site Miami Lakes Florida 33016
Neumora Investigator Site Orlando Florida 32801
Neumora Investigator Site Orlando Florida 32803
Neumora Investigator Site Orlando Florida 32807
Neumora Investigator Site Pinellas Park Florida 33782
Neumora Investigator Site Pompano Beach Florida 33060
Neumora Investigator Site Tampa Florida 33607
Neumora Investigator Site#1 Tampa Florida 33613
Neumora Investigator Site Tampa Florida 33613
Neumora Investigator Site Atlanta Georgia 30318
Neumora Investigator Site Atlanta Georgia 30328
Neumora Investigator Site Atlanta Georgia 30338
Neumora Investigator Site Marrero Louisiana 70072
Neumora Investigator Site New Orleans Louisiana 70115
Neumora Investigator Site Baltimore Maryland 21208
Neumora Investigator Site Towson Maryland 21204
Neumora Investigator Site Boston Massachusetts 02116
Neumora Investigator Site Boston Massachusetts 02131
Neumora Investigator Site Watertown Massachusetts 02472
Neumora Investigator Site Mankato Minnesota 56001
Neumora Investigator Site Princeton New Jersey 08540
Neumora Investigator Site Toms River New Jersey 08755
Neumora Investigator Site Albuquerque New Mexico 87109
Neumora Investigator Site Buffalo New York 14215
Neumora Investigator Site Inwood New York 11096
Neumora Investigator Site New York New York 10017
Neumora Investigator Site The Bronx New York 10461
Neumora Investigator Site Monroe North Carolina 28112
Neumora Investigator Site North Canton Ohio 44720
Neumora Investigator site Edmond Oklahoma 73013
Neumora Investigator Site Oklahoma City Oklahoma 73118
Neumora Investigator Site Philadelphia Pennsylvania 19104
Neumora Investigator Site North Charleston South Carolina 29405
Neumora Investigator Site Memphis Tennessee 38119
Neumora Investigator Site Austin Texas 78737
Neumora Investigator Site Dallas Texas 75243
Neumora Investigator Site Houston Texas 77030
Neumora Investigator Site Bellevue Washington 98007
Neumora Investigator Site Everett Washington 98201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06058013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 5, 2026 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06058013 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →